Effect of NFE2L2 Genetic Polymorphism on the Association Between Oral Estrogen Therapy and the Risk of Venous Thromboembolism in Postmenopausal Women.
Bouligand, J 1,2; Cabaret, O 1; Canonico, M 3,4; Verstuyft, C 1,5; Dubert, L 5; Becquemont, L 1,5; Guiochon-Mantel, A 1,2; Scarabin, P Y 3,4; for the Estrogen and Thromboembolism Risk (ESTHER) Study Group
[Report] Clinical Pharmacology & Therapeutics. 89(1):60-64, January 2011.

(Format: HTML, PDF)

: Oral, but not transdermal, estrogen therapy increases the risk of venous thromboembolism (VTE) in women who are past menopause. Data from the Estrogen and Thromboembolism Risk (ESTHER) study were used to investigate the effects of the genetic polymorphism of NFE2L2 rs6721961, which may impair Nrf2-dependent hepatic conjugation of estrogen metabolites. As compared with nonusers, the odds ratio (OR) for VTE in current users of oral estrogens was 2.5 (95% confidence interval (CI): 1.3-4.8) in patients with wildtype NFE2L2 and 17.9 (95% CI: 3.7-85.7) in those with the polymorphism (interaction, P = 0.01).

(C) 2011 John Wiley & Sons, Ltd